An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
2008

Predicting Response to Lenalidomide in Myelodysplastic Syndrome

publication Evidence: moderate

Author Information

Author(s): Azra Raza, BL Ebert, N Galili, P Tamayo, J Bosco, R Mak

Hypothesis

Can a molecular signature predict response to lenalidomide in patients with myelodysplastic syndrome?

Conclusion

The study identified a gene expression signature that can predict which patients will respond to lenalidomide treatment.

Supporting Evidence

  • The gene expression response signature was enriched in genes involved in erythroid differentiation.
  • The application of lenalidomide to primary non-MDS CD34+ cells promoted erythroid differentiation.

Takeaway

Scientists found a way to tell which patients with a blood disease called myelodysplastic syndrome will get better with a medicine called lenalidomide.

Methodology

The authors used gene expression profiling to identify a molecular signature in patients without Chromosome 5q deletions.

Limitations

The study is small and may not be robust for predicting responses in a larger, more diverse group.

Participant Demographics

Patients with myelodysplastic syndrome, specifically those without Chromosome 5q deletions.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0050035

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication